Overview: NGS Adrenoleukodystrophy Sequencing TestIntroduction: The NGS Adrenoleukodystrophy Sequencing Test sequences genes to diagnose adrenoleukodystrophy, causing neurological or adrenal issues. Following 2023 NORD guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected adrenoleukodystrophy (ALD).
Other Names: ALD Assay, ABCD1 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: ALD sequencing began in the 1990s with peroxisomal disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose adrenoleukodystrophy, guides treatment, and evaluates patients with neurological or adrenal issues.
Test Parameters: 1. Adrenoleukodystrophy Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of neurological issues, adrenal insufficiency, or ALD symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document neurological issues, adrenal insufficiency, or family history of ALD. Include current medications, especially corticosteroids.
Consent: Written consent required, detailing the tests purpose, ALD implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze ALD genes (e.g., ABCD1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for ALD diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm ALD, guiding hematopoietic stem cell transplantation or supportive care. Negative results may require VLCFA testing.
Specialist Consultation: Consult a neurologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Very long-chain fatty acid (VLCFA) testing, brain MRI, or adrenal function tests to confirm ALD diagnosis.
Test Limitations: Not all ALD cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: NORD ALD Guidelines, 2023; Neurology, Moser HW, 2022.
